
Finalization of share buyback program in Initiator Pharma

Initiator Pharma A/S (“Initiator” or the “Company”) has today finalized the share buyback that was announced on 21 June 2023.

Today the Initiator has finalized the buyback of shares that was announced on 21 June, 2023. In connection with the buy back, the Company has bought a total of 19,500 shares (“Treasury Shares”) at an average price of 7,24.

Initiator has sold the Treasury Shares to certain members of the Board of Directors under the LTI2022-program. Each share was sold at a price of DKK 0.105 per share corresponding to par value.

The aggregate gross proceeds from the sale of treasury shares are DKK 2,047.50.

For additional information about Initiator Pharma, please contact:

Claus Elsborg Olesen, CEO
Telephone: +45 6126 0035
E-mail: ceo@initiatorpharma.com

About Initiator Pharma

Initiator Pharma A/S is a Danish clinical stage emerging pharma company developing innovative drugs that target key unmet medical needs within the central and peripheral nervous system. Initiator Pharma’s pipeline consists of two clinical stage assets – pudafensine (IP2015) and IP2018 – and two preclinical assets. The company is currently conducting a Phase IIb trial with pudafensine (IP2015) in erectile dysfunction of organic origin, and successfully completed a Phase I proof of principle trial in neuropathic pain in 2022. With IP2018 the company is conducting a Phase IIa trial for the treatment of erectile dysfunction of psychogenic origin.

Initiator Pharma is listed on Nasdaq First North Growth Market (ticker: INIT). Redeye AB is the company’s Certified Adviser. For more information, please visit www.initiatorpharma.com.

Attachments

Finalization of share buyback program in Initiator Pharma